1. Home
  2. MIST vs SGA Comparison

MIST vs SGA Comparison

Compare MIST & SGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • SGA
  • Stock Information
  • Founded
  • MIST 2003
  • SGA 1986
  • Country
  • MIST Canada
  • SGA United States
  • Employees
  • MIST N/A
  • SGA N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • SGA Broadcasting
  • Sector
  • MIST Health Care
  • SGA Consumer Discretionary
  • Exchange
  • MIST Nasdaq
  • SGA Nasdaq
  • Market Cap
  • MIST 81.5M
  • SGA 89.2M
  • IPO Year
  • MIST N/A
  • SGA 1992
  • Fundamental
  • Price
  • MIST $1.80
  • SGA $12.00
  • Analyst Decision
  • MIST Strong Buy
  • SGA
  • Analyst Count
  • MIST 3
  • SGA 0
  • Target Price
  • MIST $13.00
  • SGA N/A
  • AVG Volume (30 Days)
  • MIST 510.8K
  • SGA 14.8K
  • Earning Date
  • MIST 11-12-2024
  • SGA 11-07-2024
  • Dividend Yield
  • MIST N/A
  • SGA 8.35%
  • EPS Growth
  • MIST N/A
  • SGA N/A
  • EPS
  • MIST N/A
  • SGA 0.75
  • Revenue
  • MIST N/A
  • SGA $110,669,000.00
  • Revenue This Year
  • MIST N/A
  • SGA $0.49
  • Revenue Next Year
  • MIST N/A
  • SGA $0.18
  • P/E Ratio
  • MIST N/A
  • SGA $16.00
  • Revenue Growth
  • MIST N/A
  • SGA N/A
  • 52 Week Low
  • MIST $1.12
  • SGA $11.78
  • 52 Week High
  • MIST $3.52
  • SGA $27.00
  • Technical
  • Relative Strength Index (RSI)
  • MIST 68.42
  • SGA 23.74
  • Support Level
  • MIST $1.75
  • SGA $12.04
  • Resistance Level
  • MIST $2.09
  • SGA $14.09
  • Average True Range (ATR)
  • MIST 0.15
  • SGA 0.41
  • MACD
  • MIST 0.04
  • SGA -0.21
  • Stochastic Oscillator
  • MIST 62.86
  • SGA 3.59

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets and It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

Share on Social Networks: